Kevan M. Shokat, PhD

Reed College (Portland, Oregon), B.A., 1986, Chemistry
UC Berkeley (Berkeley, California), Ph.D., 1991, Organic Chemistry

• 1986-1991
  (Advisor: Prof. Peter G. Schultz, UC Berkeley): Design and synthesis of haptens for the generation of catalytic antibodies. Thesis Title: New Routes to Catalytic Antibodies.
• 1992-1994
  (Advisor: Prof. Christopher C. Goodnow, Stanford University): Investigation of mechanisms of immune self-tolerance in transgenic mice.
• 1994-1998
  Assistant Professor of Chemistry and Molecular Biology, Princeton University
• 1998-1999
  Associate Professor of Chemistry and Molecular Biology, Princeton University
• 1999-2002
  Associate Professor of Cellular and Molecular Pharmacology, University of California, San Francisco
• 1999-2002
  Associate Professor of Chemistry, University of California, Berkeley
• 2001-present
  Professor of Cellular and Molecular Pharmacology, University of California, San Francisco
• 2002-present
  Professor of Chemistry, University of California, Berkeley
• 2004-present
  Vice-Chairman of Cellular and Molecular Pharmacology, UCSF
• 2004-present
  Investigator, Howard Hughes Medical Institute

• 1986
  Phi Beta Kappa - Reed College
• 1986-1987
  UC Berkeley Regents Fellowship
• 1989-1990
  UC Berkeley University Fellowship
• 1992-1994
  Life Sciences Research Foundation Postdoctoral Fellow
• 1995-1997
  NSF Early Career Development Award
• 1996-2000
  Pew Scholar in the Biomedical Sciences
• 1997-1998
  Glaxo-Wellcome Scholar in Organic Chemistry
• 1997-2000
  Searle Scholar
• 1997-2000
  Cottrell Scholar
• 1999-2001
  Alfred P. Sloan Research Fellow
• 2001
  Protein Society Young Investigator Award
• 2002
  Eli Lilly Award in Biological Chemistry

• Provance DW Jr, Gourley CR, Silan CM, Cameron LC, Shokat KM, Goldenring JR, Shah K, Gillespie PG, Mercer JA. (2004) From the Cover: Chemical-genetic inhibition of a sensitized mutant myosin Vb demonstrates a role in peripheral-pericentriolar membrane traffic. Proc. Natl. Acad. Sci. USA. 17:101(7):1868-73.
• Simon, M.D. and Shokat, K.M.* (2004) Adaptability at a protein-DNA interface: re-engineering the engrailed homeodomain to recognize an unnatural nucleotide. J. Am. Chem. Soc. 126(26):8078-79.
• Sato, K., Simon, M.D., Levin, A.M., Gothard, C.M., Shokat, K.M. and Weiss, G.A. (2004) Dissecting the Engrailed-DNA Interaction by Phage-Displayed Alanine Shotgun Scanning. Chem. Biol. 11(7):1017-23.
• Knight, Z.A., Chiang, G., Alaimo, P.J., Kenski, D.M., Ho, C.B., Coan, K., Abraham, R., and Shokat, K.M. (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. & Med. Chem. Ltrs., in press.
• Maly, D.J., Allen, J.A. and Shokat, K.M. (2004) A Mechanism-Based Crosslinker for the Identification of Kinase-Substrate Pairs. J. Am. Chem. Soc., 126(30):9160-61.
• Simon, M.D., Sato, K., Weiss, G.A. and Shokat, K.M. (2004) A phage display selection of engrailed homeodomain mutants and the importance of residue Q50. Nucleic Acids Res. 32(12):3623-31.
• Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K.M. and Witte, O.N. (2004) Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A., 101(50):17456-61.
• Kunkel, E.J., Plavec, I., Nguyen, D., Melrose, J., Rosler, E.S., Kao, L.T., Wang, Y., Hytopoulos, E., Bishop, A.C., Bateman, R., Shokat, K.M., Butcher, E.C. and Berg, E.L. (2004) Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev Technol., 2(4):431-41.
• Jones, M.H., Huneycutt, B.J., Pearson, C.G., Zhang, C., Morgan, G., Shokat, K., Bloom, K., Winey, M. (2005) Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr Biol., 15(2):160-5.
• Kung, C. and Shokat, K.M. (2005) Small-Molecule Kinase-Inhibitor Target Assessment. Chembiochem, 6(3):523-526.
• Kung C, Kenski DM, Dickerson SH, Howson RW, Kuyper LF, Madhani HD, Shokat KM. (2005) Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl. Acad. Sci., 102(10)3587-3592.
• Alaimo, P.J., Knight, Z.A. and Shokat, K.M. (2005) Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg & Med Chem, 12:2825-2836.
• Chen, X., Ye, H., Kuruvilla, R., Ramanan, N., Scangos, K.W., Zhang, C., Johnson, N.M., England, P.M., Shokat, K.M. and Ginty, D.D. (2005) A chemical-genetic approach to studying neurotrophin signaling. Neuron, 46(1):13-21.
• Allen, J., Lazerwith, S.E. and Shokat, K.M. (2005) Bio-orthogonal Affinity Purification of Direct Kinase Substrates. J. Amer. Chem. Soc., 127(15):5288-5289.
• Murattani, M., Kung, C, Shokat, K.M. and Tansey, W.P. (2005) The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell, 120(6):887-899.
• Shokat, K.M. (2005) Chemicals Call Bacteria, and A New Membrane Protein Machine Answers. Cell, 121:163-166.
• Masahiro Tanaka, Raynard Bateman, Daniel Rauh, Eugeni Vaisberg, Shyam Ramachandani, Chao Zhang, Kirk C. Hansen, Alma L. Burlingame, Jay K. Trautman, Kevan M. Shokat, and Cynthia L. Adams (2005) An Unbiased Cell Morphology Based Screen for New Biologically Active Small Molecules. PLOS Biology, 3(5):e128.
• Knight, Z.A. and Shokat, K.M. (2005) Features of selective kinase inhibitors. Chemistry & Biology, 12:621-637.
• Cohen, M.C., Zhang, C., Shokat, K.M., Taunton, J. (2005) Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science, 308:1318-1321.
• Chao Zhang, Denise M. Kenski, Jennifer L. Paulson, Arale Bonshtien, Guido Sessa, Janet V. Cross, Dennis J. Templeton, and Kevan M. Shokat. (2005) A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nature Methods, 2(6):435-441.
• Kenski, D.M., Zhang, C., von Zastrow, M. and Shokat, K.M. (2005) Chemical genetic engineering of G protein-coupled receptor kinase 2. J. Biol. Chem., 80(41):35051-61.
• D'Aquino, K.E., Monje-Casas, F., Paulson, J., Reiser, V., Charles, G.M., Lai, L., Shokat, K.M. and Amon, A. (2005)The protein kinase Kin4 inhibits exit from mitosis in response to spindle position defects. Mol. Cell., 19(2):223-34.
• Juris, S.J., Shah, K., Shokat, K., Dixon, J.E. and Vacratsis, P.O.(2006) Identification of otubain 1 as a novel substrate for the Yersinia protein kinase using chemical genetics and mass spectrometry. FEBS Lett., 580(1):179-83.
• Dephoure, N., Howson, R.W., Blethrow, J.D., Shokat, K.M. and O'Shea, E.K. (2005) Combining chemical genetics and proteomics to identify protein kinase substrates. Proc Natl Acad Sci U S A., 102(50):17940-5.
• Larochelle, S., Batliner, J., Gamble, M.J., Barboza, N.M., Kraybill, B.C., Blethrow, J.D., Shokat, K.M. and Fisher, R.P. (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol., 13(1):55-62.
• Pinsky, B.A., Kung, C., Shokat, K.M. and Biggins, S. (2006) The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol., 8(1):78-83.
• Ventura, J.J., Hubner, A., Zhang, C., Flavell, R.A., Shokat, K.M. and Davis, R.J. -(2006) Chemical Genetic Analysis of the Time Course of Signal Transduction by JNK. Mol Cell. 21(5):701-10.
• Knight, Z.A., Gonzalez-Perez, B., Feldman, M.E., Zunder, E., Goldenberg, D., Balla, A., Balla, T., Loewith, R., Weiss W.A., Williams, R.L. and Shokat, K.M. (2006) A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell, 125(4):733-47.
• Kung, C., Kenski, D.M., Krukenberg, K., Madhani, H.D. and Shokat, K.M. (2006) Selective kinase inhibition by exploiting differential pathway sensitivity. Chem Biol. Apr;13(4):399-407.
• Wohlbold, L., Larochelle, S., Liao, J.C., Livshits, G., Singer, J., Shokat, K.M. and Fisher, R.P. (2006) The cyclin-dependent kinase (CDK) Family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle, 5(5):546-54.
• Sturgeon, C.M., Knight, Z.A., Shokat, K.M. and Roberge, M. (2006) Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol. Cancer Ther., 5(4):885-892.
• Fan, Q-W., Knight, Z.A., Goldenberg, D.D., Yu, W., Mostov, K.E., Stokoe, D., Shokat, K.M. and Weiss, W.A. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 9:341-349.
• Wei, F., Wang, G.D., Zhang, C., Shokat, K.M., Wang, H., Tisen, J.Z., Liauw, J. and Zhuo, M. (2006) Forebrain overexpression of CaMKII abolishes cingulate long term depression and reduces mechanical allodynia and thermal hyperalgesia. Mol. Pain., 15;2(1):21.
• Brodersen, P., Petersen, M., Bjorn Nielsen, H., Zhu, S., Newman, M.A., Shokat, K.M., Rietz, S., Parker, J. and Mundy, J. (2006) Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J., 47(4):532-46.
• Van Keymeulen, A., Wong, K., Knight, Z.A., Govaerts, C., Hahn, K.M., Shokat, K.M. and Bourne, H.R. (2006) To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol., 174(3):437-45.
• Jaeschke, A., Karasarides, M., Ventura, J.J., Ehrhardt, A., Zhang, C., Flavell, R.A., Shokat, K.M. and Davis, R.J. (2006) JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell. 23(6):899-911.
• Toth, B., Balla, A., Ma, H., Knight, Z.A., Shokat, K.M. and Balla, T. (2006) Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem., Sept 26; [Epub ahead of print]
• Wan, L., Zhang, C., Shokat, K.M., Hollingsworth, N.M. (2006) Chemical inactivation of Cdc7 kinase in budding yeast results in a reversible arrest that allows efficient cell synchronization prior to meiotic recombination. Genetics, Oct 22; [Epub ahead of print]